Kailera Q1 net loss $78.9M; advances obesity pipeline with Phase 3 start and positive data

Kailera Therapeutics, Inc.

Net loss of $78.9M in Q1 2026 vs $18.0M in Q1 2025; R&D expenses rose to $70.9M from $10.1M.
Cash $581.9M plus IPO proceeds of $718.8M expected to fund operations into mid-2028.
Initiated global Phase 3 KaiNETIC program for ribupatide injection; data expected 2028.
Positive Phase 2 oral ribupatide data: mean weight loss up to 12.1% at week 26; Phase 3 trials planned for early 2027.
Positive Phase 1 data for KAI-4729 tri-agonist: up to 16.0% weight loss at 12 weeks; Phase 1 outside China planned 2026.

item 2.02 item 9.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001193125-26-239362
form_type: 8-K
ticker: KLRA
cik: 0002096997
company_name: Kailera Therapeutics, Inc.
filed_at: 2026-05-26T20:18:46+00:00
discovered_at: 2026-05-26T20:20:00.443765+00:00
generated_at: 2026-05-26T20:21:20.754452+00:00
sec_items: ["2.02", "9.01"]
event_type: earnings
sentiment: positive
materiality_score: 0.75
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001193125-26-239362
json_url: https://secwatch.observer/filing/0001193125-26-239362.json
markdown_url: https://secwatch.observer/filing/0001193125-26-239362.md
text_url: https://secwatch.observer/filing/0001193125-26-239362.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/2096997/000119312526239362/0001193125-26-239362-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/2096997/000119312526239362/ck0002096997-20260526.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Source: SEC EDGAR

accession 0001193125-26-239362

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.